MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
6.75
-0.58 (-7.91%)
Mar 31, 2025, 1:15 PM EDT - Market open
MeiraGTx Holdings Revenue
In the year 2024, MeiraGTx Holdings had annual revenue of $33.28M with 137.42% growth. MeiraGTx Holdings had revenue of $21.39M in the quarter ending December 31, 2024, with 948.53% growth.
Revenue (ttm)
$33.28M
Revenue Growth
+137.42%
P/S Ratio
15.38
Revenue / Employee
$87,346
Employees
381
Market Cap
532.27M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MGTX News
- 6 days ago - MeiraGTx Holdings: Gaining Regulatory Focus - Seeking Alpha
- 18 days ago - MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars - Benzinga
- 18 days ago - MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates - GlobeNewsWire
- 18 days ago - MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process - GlobeNewsWire
- 5 weeks ago - MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy - GlobeNewsWire
- 2 months ago - MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value - Seeking Alpha
- 2 months ago - MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations - GlobeNewsWire
- 4 months ago - MeiraGTx Holdings: Behind The Recent Rally - Seeking Alpha